Results 101 to 110 of about 17,623 (143)

Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection

Infection and Drug Resistance
Ignacy Tarski,1 Jakub Śmiechowicz,2 Wiesława Duszyńska2 1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; 2Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw ...
Tarski I, Śmiechowicz J, Duszyńska W
doaj  

Aggressive joint pharmacokinetic/pharmacodynamic target attainment of TDM-guided continuous infusion meropenem-vaborbactam monotherapy: a valuable strategy for maximizing the microbiological outcome of documented KPC-producing Enterobacterales infections?

Objective: To assess whether attaining an aggressive joint pharmacokinetic/pharmacodynamic (PK/PD) target of therapeutic drug monitoring (TDM)-guided continuous infusion (CI) meropenem-vaborbactam monotherapy may be a valuable strategy for maximizing the
Giorgi, Beatrice, Secci, Benedetta, Gatti, Milo, Viale, Pierluigi, Bonazzetti, Cecilia, Tonetti, Tommaso, Cojutti, Pier Giorgio, Siniscalchi, Antonio, Pea, Federico, Ambretti, Simone, Rinaldi, Matteo   +10 more
core   +1 more source

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +2 more sources

Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen. [PDF]

Int J Antimicrob Agents, 2023
Singh S, Gumbo T, Alffenaar JW, Boorgula GD, Shankar P, Thomas TA, Dheda K, Malinga L, Raj P, Aryal S, Srivastava S.   +10 more
europepmc   +1 more source

Effect of meropenem-vaborbactam vs piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection the TANGO I randomized clinical trial

, 2018
IMPORTANCE Meropenem-vaborbactam is a combination carbapenem/beta-lactamase inhibitor and a potential treatment for severe drug-resistant gram-negative infections.
Alexander, E.L., Chorvat, E., Sarychev, Y., Kaye, K.S., Horcajada, J.P., Vazquez, J., Giamarellos-Bourboulis, E.J., Fusaro, K., Sagan, O.S., Dudley, M.N., Bleasdale, S.C., Fedosiuk, E., Stus, V., Metallidis, S., Morgan, E., Bhowmick, T., Zaitsev, V., Stoev, V., Murta, C., Bidair, M., Dragoescu, P.O., Griffith, D., Lomovskaya, O., Loutit, J.   +23 more
core   +1 more source

Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case reports and review of the literature

Recently, an increase in cases of multidrug-resistant Gram-negative bacteria post-neurosurgical ventriculitis and meningitis is reported. Treating these infections has become challenging due to the limited availability of antibiotics and the need to ...
Benedetti, Sara, Tumbarello, Mario, Tarantino, Francesca, Sambo, Margherita, Castellani, Paola, Giuliano, Gabriele   +5 more
core   +1 more source

Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). [PDF]

J Antimicrob Chemother
Sader HS, Papp-Wallace KM, Kimbrough JH, Debabov D, Mendes RE, Castanheira M.   +5 more
europepmc   +1 more source

Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis. [PDF]

Mediterr J Hematol Infect Dis
Marzi F, Alessandri M, De Crescenzo V, Del Vecchio S, Radi S, Manini M.   +5 more
europepmc   +1 more source

Complete genome sequences of KPC-producing <i>Klebsiella pneumoniae</i> isolates pre- and post-development of meropenem/vaborbactam resistance. [PDF]

Microbiol Resour Announc
Ozer EA, Nozick SH, Singh N, Watkins JV, Hauser AR, Bulman ZP.   +5 more
europepmc   +1 more source

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance. [PDF]

Antibiotics (Basel), 2023
Duda-Madej A, Viscardi S, Topola E.
europepmc   +1 more source